Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NKF-PEG vs US-Neulasta in Healthy Adult Male Volunteers
NCT07738991Phase 1Recruiting
- Sponsor
- Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd.
- Start
- Jul 2026
- Primary completion
- Nov 2026
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of NKF-PEG in neutropenia (2 arms), sponsored by Nanjing King-Friend Biochemical Pharmaceutical Co., Ltd. Primary endpoints: Area Under the Concentration-Time Curve From Time Zero to the Last Measurable Concentration, Maximum Observed Concentration and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
NKF-PEG
03
Conditions
neutropenia
Beyond the preview
Go deeper on NCT07738991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07738991.